View article

Given their genotypic and phenotypic correlation with in vivo tumours, patient-derived organoids (PDOs) are in increasing use as pre-clinical models for High Grade Serous Ovarian Cancer (HGSOC) and other malignancies. We sought to characterise inter- and intra-patient transcriptomic heterogeneity in PDOs from disseminated HGSOC and assess gene expression changes following cisplatin and PARP inhibitor treatment.

PDOs were established from multi-site tumours from patients undergoing primary cytoreductive surgery, tumour cells extracted, PDOs propagated using different media conditions (±R-spondin), and assessed for their responses to conventional and targeted therapeutics. PDO lines derived from 3 different patients were selected for growth in low dose cisplatin or rucaparib to model resistance. RNA-sequencing was performed to characterise transcriptomic …